3-Iodobenzaldehyde[4-(diphenylamino)-6-(4-morpholinyl)-1,3,5-triazin-2-yl]hydrazone
3-Iodobenzaldehyde[4-(diphenylamino)-6-(4-morpholinyl)-1,3,5-triazin-2-yl]hydrazone
3-Iodobenzaldehyde[4-(diphenylamino)-6-(4-morpholinyl)-1,3,5-triazin-2-yl]hydrazone 性质
沸点 | 719.7±70.0 °C(Predicted) |
---|---|
密度 | 1.53±0.1 g/cm3(Predicted) |
储存条件 | 2-8°C |
溶解度 | DMSO:18.33(最大浓度 mg/mL);31.74(最大浓度 mM) DMSO:PBS (pH 7.2) (1:7):0.12(最大浓度 mg/mL);0.21(最大浓度.mM) DMF:3.0(最大浓度 mg/mL);5.2(最大浓度 mM) |
形态 | 白色固体 |
酸度系数(pKa) | 10.74±0.10(Predicted) |
颜色 | 白色至米白色 |
3-Iodobenzaldehyde[4-(diphenylamino)-6-(4-morpholinyl)-1,3,5-triazin-2-yl]hydrazone 用途与合成方法
Target | Value |
PIKfyve
() |
Vacuolin-1 (1 μM; Pretreatment 1 hour) blocks ionomycin-induced exocytosis of lysosomes but not of enlargeosomes. It results in vacuolation of lysosomes (A) and complete inhibition of the surface expression of Lamp-1. Vacuolin-1 (1 μM; 20-180 min) disrupts the segregation of inner and limiting membranes characteristic of endosomes and lysosomes. Ultrastructural analysis also shows that vacuolin-1 favours fusion of inner and limiting membranes. Vacuolin-1 (5 or 10 μM; 2 hours) blocks the Ca 2+ -dependent release of β-hexosaminidase from lysosomes. In HeLa cells, ionomycin results in the expected release of 18-20% of lysosomal β-hexosaminidase. But when cells pretreated with vacuolin-1, releases no more β-hexosaminidase compared with cells that are not exposed to ionomycin (4%).
3-Iodobenzaldehyde[4-(diphenylamino)-6-(4-morpholinyl)-1,3,5-triazin-2-yl]hydrazone 价格(试剂级)
更新日期 | 产品编号 | 产品名称 | CAS号 | 包装 | 价格 |
---|---|---|---|---|---|
2025-02-05 | HY-118630 | 3-Iodobenzaldehyde[4-(diphenylamino)-6-(4-morpholinyl)-1,3,5-triazin-2-yl]hydrazone | 351986-85-1 | 5mg | 900 |
2025-02-05 | HY-118630 | 3-Iodobenzaldehyde[4-(diphenylamino)-6-(4-morpholinyl)-1,3,5-triazin-2-yl]hydrazone | 351986-85-1 | 10mg | 1400 |